Sleep Medicine, Год журнала: 2024, Номер 124, С. 134 - 140
Опубликована: Сен. 14, 2024
Язык: Английский
Sleep Medicine, Год журнала: 2024, Номер 124, С. 134 - 140
Опубликована: Сен. 14, 2024
Язык: Английский
Revue Neurologique, Год журнала: 2023, Номер 179(7), С. 782 - 792
Опубликована: Авг. 21, 2023
Язык: Английский
Процитировано
3Cancers, Год журнала: 2024, Номер 16(6), С. 1127 - 1127
Опубликована: Март 12, 2024
Background: Vasomotor symptoms (VMSs) associated with menopause represent a significant challenge for many patients after cancer treatment, particularly if conventional menopausal hormone therapy (MHT) is contraindicated. Methods: The Menopause Cancer (MAC) Study (NCT04766229) was single-arm phase II trial examining the impact of composite intervention consisting (1) use non-hormonal pharmacotherapy to manage VMS, (2) digital cognitive behavioral insomnia (dCBT-I) using Sleepio (Big Health), (3) self-management strategies VMS delivered via myPatientSpace mobile application and (4) nomination an additional support person/partner on quality life (QoL) in women moderate-to-severe cancer. primary outcome change cancer-specific global QoL assessed by EORTC QLC C-30 v3 at 6 months. Secondary outcomes included frequency bother/interference symptoms. Results: In total, 204 (82% previous breast cancer) median age 49 years (range 28–66) were recruited. A total 120 completed protocol. Global scores increased from 62.2 (95%CI 58.6–65.4) 70.4 67.1–73.8) months (p < 0.001) intention treatment (ITT) cohort (n = 204) 62 per-protocol (PP) 120). At least 50% reductions noticed as well degree six prevalence reduced 93.1% baseline 45.2% 0.001). Sleep Condition Indicator 8.5 (SEM 0.4) 17.3 0.5) 0.0005) ITT 7.9 PP cohort. Conclusions: targeted improves frequent bothersome vasomotor benefits frequency,
Язык: Английский
Процитировано
0Sleep Medicine, Год журнала: 2024, Номер 124, С. 134 - 140
Опубликована: Сен. 14, 2024
Язык: Английский
Процитировано
0